Get the Stockscreener App
1.45
17.61%
-0.31
After Hours:
1.47
0.02
+1.38%
Clearmind Medicine Inc stock is traded at $1.45, with a volume of 102.95K.
It is down -17.61% in the last 24 hours and down -41.77% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$1.76
Open:
$1.8101
24h Volume:
102.95K
Relative Volume:
0.27
Market Cap:
$2.17M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.034
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-33.79%
1M Performance:
-41.77%
6M Performance:
-96.30%
1Y Performance:
-97.57%
1-Day Range:
$1.33
$1.8595
1-Week Range:
$1.33
$2.4105
52-Week Range:
$1.33
$59.60
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.45 | 2.64M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.81 | 119.38B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.63 | 81.46B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
820.31 | 52.65B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 46.50B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.00 | 38.95B | 4.98B | 69.60M | 525.67M | 0.5198 |
Clearmind Medicine Inc Stock (CMND) Latest News
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ ... - Caledonian Record
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - Yahoo Finance
Breakouts Watch: Is Clearmind Medicine Inc a strong growth stock - baoquankhu1.vn
Aug Retail: Is Clearmind Medicine Inc stock a buy or sellQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Aug Macro: Does Varonis Systems Inc have a competitive edgeJobs Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Clearmind Medicine registers 17M shares for resale linked to $10M convertible note deal - MSN
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 - The Manila Times
Clearmind Medicine Inc. Files Annual Report on Form 20-F for Fiscal Year Ended October 31, 2025 - Quiver Quantitative
Clearmind Medicine: Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk - TradingView
Will Clearmind Medicine Inc. stock deliver shareholder valueDay Trade & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine (NASDAQ:CMND) Shares Up 0.4% – What’s Next? - Defense World
Clearmind completes treatment for second cohort in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind announces completion of treatment for second cohort in CMND-100 trial - TipRanks
Clearmind Completes Treatment In 2nd Cohort Of CMND-100 Phase I/IIa Trial In Alcohol Use Disorder - Nasdaq
Clearmind completes treatment for second cohort in AUD drug trial - Investing.com
Clearmind Medicine IncTopline results from second cohort of CMND-100 expected in coming months - marketscreener.com
Clearmind Medicine Inc. Completes Treatment for Second Cohort in Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock News - Quiver Quantitative
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 - The Manila Times
6 patients finish Clearmind trial testing new alcohol use disorder drug - Stock Titan
Will Clearmind Medicine Inc. outperform tech stocks2025 Trading Recap & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Aug Final Week: Does Clearmind Medicine Inc stock trade at a discount to peersJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Bộ Nội Vụ
Risk On: Is Clearmind Medicine Inc a potential multi bagger2025 Valuation Update & Safe Entry Zone Tips - baoquankhu1.vn
Why Clearmind Medicine Inc. stock remains on buy listsTrail vs Road Selection & compare fit, width, and feel - Улправда
Published on: 2026-01-09 01:57:04 - Улправда
Does Clearmind Medicine Inc. (CWY0) stock trade below intrinsic valueQuarterly Investment Review & Scalable Portfolio Growth Methods - Улправда
Will Clearmind Medicine Inc. stock benefit from AI adoptionStock Buy Signals & Target Triple-Digit Stock Opportunities - ulpravda.ru
Surprises Report: Why Clearmind Medicine Inc stock is recommended by analystsChart Signals & Safe Swing Trade Setups - Bộ Nội Vụ
How geopolitical tensions affect Clearmind Medicine Inc. stock2026 world cup usa national team group stage defensive leaders possession football match prediction insights - Улправда
Why retail traders accumulate Clearmind Medicine Inc. (CWY0) stockStop Loss Placement Tips & Build Wealth With Zero-Cost Tools - bollywoodhelpline.com
Portfolio Shifts: Why Clearmind Medicine Inc stock is recommended by analystsRate Cut & Reliable Price Action Trade Plans - moha.gov.vn
Clearmind Medicine (CMND) Stock Analysis Report | Financials & Insights - Benzinga España
Clearmind Medicine Announces the Notice of an International Patent App... - Moscow-Pullman Daily News
Clearmind regains Nasdaq compliance as shares maintain $1 minimum By Investing.com - Investing.com Nigeria
Clearmind regains Nasdaq compliance as shares maintain $1 minimum - Investing.com India
Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule - MarketScreener
Clearmind Medicine regains compliance with Nasdaq minimum bid price rule - TipRanks
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Requirements | CMND Stock News - Quiver Quantitative
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Clearmind Medicine highlights key 2025 achievements - MSN
Clearmind advances AUD treatment as phase I/IIa trial progresses By Investing.com - Investing.com Australia
Clearmind advances AUD treatment as phase I/IIa trial progresses - Investing.com
Clearmind Medicine Inc. Reflects on Major Progress in 2025 Clinical Trials for CMND-100 Targeting Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth - Yahoo Finance
Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial - MSN
San Gabriel Valley Tribune - FinancialContent
Cash from operating activities of Clearmind Medicine Inc. – MUN:CWY - TradingView — Track All Markets
Trading Recap: How strong is Clearmind Medicine Inc. stock balance sheetJuly 2025 Selloffs & Weekly Setup with ROI Potential - moha.gov.vn
How interest rate cuts could boost Clearmind Medicine Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - Улправда
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
2.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):